KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TAK) Invested Capital (2018 - 2026)

Takeda Pharmaceutical has reported Invested Capital over the past 9 years, most recently at $77.4 billion for Q1 2026.

  • For Q1 2026, Invested Capital rose 3.17% year-over-year to $77.4 billion; the TTM value through Mar 2026 reached $77.4 billion, up 3.17%, while the annual FY2026 figure was $80.7 billion, 7.32% up from the prior year.
  • Invested Capital was $77.4 billion for Q1 2026 at Takeda Pharmaceutical, up from $75.1 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $86.3 billion in Q1 2022 and bottomed at $75.1 billion in Q1 2025.
  • The 5-year median for Invested Capital is $81.2 billion (2023), against an average of $80.4 billion.
  • Year-over-year, Invested Capital dropped 8.21% in 2025 and then increased 3.17% in 2026.
  • Over 5 years, Invested Capital stood at $86.3 billion in 2022, then dropped by 5.96% to $81.2 billion in 2023, then rose by 0.74% to $81.8 billion in 2024, then fell by 8.21% to $75.1 billion in 2025, then grew by 3.17% to $77.4 billion in 2026.
  • The last three reported values for Invested Capital were $77.4 billion (Q1 2026), $75.1 billion (Q1 2025), and $81.8 billion (Q1 2024) per Business Quant data.